Tiziana Plans Phase 2 Clinical Study in Moderate to Severe Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody Since the anti-inflammatory effect of the nasally administer

Tiziana Plans Phase 2 Clinical Study in Moderate to Severe

Covid-19 Patients with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

New York/London, 30 March 2021 - Tiziana Life Sciences plc (Nasdaq:

TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics

for oncology, inflammation, and infectious diseases, reports that it plans further development of Foralumab, its proprietary anti-CD3

human monoclonal antibody in Covid-19. A recent clinical study in mild to moderate Covid-19 patients showed evidence that the nasally

administered anti-CD3 monoclonal antibody reduced pulmonary and systemic inflammation and it was well tolerated. That study was

completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA), and INTRIALS, a full-service Latin

American CRO based in S o Paulo, Brazil. Tiziana now plans a phase 2 randomized, placebo-controlled trial in Brazil for

moderate to severe hospitalized Covid-19 patients to test the drug in a more compromised group of patients. All patients will receive

standard of care background therapy.

Recent studies suggest that the pathogenesis of pulmonary inflammation

in Covid-19 includes an abnormal host response or overreaction of the immune system in patients. Therefore, nasal treatment with

Foralumab, a fully human anti-CD3 mAb, to modulate the immune system and to stimulate Tregs is a scientifically logical approach

for the treatment of Covid-19. Foralumab is also the only monoclonal antibody that can be dosed nasally or orally due to its ability

to effect systemic immunity via the epithelial lining of the nose, respiratory tract and gut.

"I am pleased to see this novel dosing concept for anti-CD3

advance to a phase 2 clinical trial. These types of human trials are important to validate the successful studies we conducted

in animal models of several inflammatory diseases," said Professor Howard Weiner, the Robert L. Kroc Professor of Neurology

at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis Center, and Co-Director of the Ann Romney

Center for Neurologic Diseases at the Brigham & Women's Hospital.

This study is expected to serve as a further proof of concept

for Foralumab's novel method of nasal delivery, as well as its safety and efficacy as a potent, systemic anti-inflammatory

therapeutic in more severe Covid-19 patients.

Covid-19 enters through the nasal and respiratory passage; accordingly,

the proprietary nasal formulation and nasal delivery of Foralumab to modulate immunity are expected to delay progression of the

disease and to provide immediate relief to Covid-19 patients.

Dr Neil Graham, Chief Medical Officer at Tiziana Life Sciences,

commented, "We are excited about this next important step in our goal to validate our drug candidate and our novel delivery

system as a promising and innovative approach to immunomodulatory therapy for Covid-19 and other mutant variants. By focusing on

moderating the inflammatory consequences of the SARS CoV2 virus, we hope to have a therapy that has efficacy irrespective of local

Foralumab (formerly NI-0401), the only entirely human anti-CD3

mAb, shows reduced release of cytokines after IV administration in patients with Crohn's disease with decreases in the classic

side effects of cytokine release syndrome and improves the overall safety profile of Foralumab. In a humanized mouse model (NOD/SCID

IL2 c-/-), it was shown that whilst targeting the T cell receptor, orally administered Foralumab modulates immune responses

of the T cells, enhances regulatory T-cells (Tregs) and thus provides therapeutic benefit in treating inflammatory and autoimmune

diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy (Ogura M. et al., 2017).

Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune

and inflammatory diseases in a safe manner by the induction of Tregs.

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & LSE: TILS) biotechnology company that focuses on the discovery

and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to Milciclib,

the Company will be shortly initiating Phase 2 studies with orally administered Foralumab for Crohn's Disease and nasally

administered Foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody ("mAb")

in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory

diseases, such as Crohn's Disease, multiple sclerosis, type-1 diabetes ("T1D"), inflammatory bowel disease ("IBD"),

psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development

of anti-Interleukin 6 receptor ("IL6R") mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation,

especially for treatment of COVID-19 patients.

For further enquiries: